CannBioRx Life Sciences Corp Asset Resilience Ratio
CannBioRx Life Sciences Corp asset resilience ratio. CannBioRx Life Sciences Corp (ATNFW) has an Asset Resilience Ratio of 93.46% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ATNFW cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CannBioRx Life Sciences Corp (2017–2019)
Asset resilience ratio of CannBioRx Life Sciences Corp from 2017 to 2019. This chart shows how CannBioRx Life Sciences Corp's Asset Resilience Ratio has changed over time. Read CannBioRx Life Sciences Corp debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CannBioRx Life Sciences Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CannBioRx Life Sciences Corp assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.30 Billion | 93.46% |
| Total Liquid Assets | $10.30 Billion | 93.46% |
Asset Resilience Insights
- Very High Liquidity: CannBioRx Life Sciences Corp maintains exceptional liquid asset reserves at 93.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CannBioRx Life Sciences Corp Industry Peers by Asset Resilience Ratio
Compare CannBioRx Life Sciences Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
CannBioRx Life Sciences Corp Asset Resilience Ratio by Year (2017–2019)
CannBioRx Life Sciences Corp asset resilience ratio by year from 2017 to 2019. The table below shows the annual Asset Resilience Ratio data for CannBioRx Life Sciences Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 22.89% | $11.88 Million | $51.88 Million | -76.88pp |
| 2018-12-31 | 99.77% | $118.17 Million | $118.44 Million | +0.17pp |
| 2017-12-31 | 99.60% | $116.59 Million | $117.06 Million | -- |
About CannBioRx Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more